DACPLAT
Categoria
DACPLAT Nombres de marca, DACPLAT Analogos
DACPLAT Marca los nombres de mezcla
DACPLAT Formula quimica
DACPLAT RX enlace
DACPLAT FDA hoja
DACPLAT MSDS (hoja de seguridad de materiales)
DACPLAT Sintesis de referencia
DACPLAT Peso molecular
DACPLAT Punto de fusion
DACPLAT H2O Solubilidad
DACPLAT Estado
DACPLAT LogP
DACPLAT Formas de dosificacion
DACPLAT Indicacion
DACPLAT Farmacologia
DACPLAT Absorcion
DACPLAT Toxicidad
DACPLAT Informacion de Pacientes
Patients and patientsí caregivers should be informed of the expected side effects of ELOXATIN, particularly its neurologic effects, both the acute, reversible effects, and the persistent neurosensory toxicity. Patients should be informed that the acute neurosensory toxicity may be precipitated or exacerbated by exposure to cold or cold objects. Patients should be instructed to avoid cold drinks, use of ice, and should cover exposed skin prior to exposure to cold temperature or cold objects.
Patients must be adequately informed of the risk of low blood cell counts and instructed to contact their physician immediately should fever, particularly if associated with persistent diarrhea, or evidence of infection develop.
Patients should be instructed to contact their physician if persistent vomiting, diarrhea, signs of dehydration, cough or breathing difficulties occur, or signs of allergic reaction appear.
